Business Parks & Science Centres

 
 
 

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px
Organisation › Details

Horizon Discovery Group plc (LSE: HZD)

Horizon Discovery Limited (Horizon) is a leading provider of research tools to support translational genomics research and the development of personalized medicines. The Company's proprietary technology, GENESIS, is the world's most precise genome editing technology. Using GENESIS, Horizon is able to alter any endogenous gene sequence of a human or mammalian cell-line quickly, reliably and without introducing unwanted and confounding genotypes and/or phenotypes. Horizon has harnessed GENESIS to create over 400 X-MAN cell lines, the world's first source of genetically-defined and patient-relevant human cell lines, accurately modeling the disease-causing mutations found in cancer patients. These 'patients-in-a-test-tube' are being used by academic and industry leaders to identify the effect of individual genetic mutations on drug activity, patient responsiveness, and resistance, leading to the successful prediction of which patient sub-groups will respond to currently-available and future drug treatments. This enables the design of shorter, more focused, and less expensive clinical trials, ultimately providing the tools to identify the 'right drugs' for the 'right patients' based upon the unique genetic mutations that define their disease. In addition to the X-MAN cell lines, Horizon provides GENESIS and X-MAN derived products and services, with industrial application in: bio-pharmaceutical process optimization; clinical diagnostic development; drug discovery & development; and the provision of reference standards for genomic-based clinical research platforms. *

 

Period Start 2007-06-01 established
  Group Horizon Discovery (Group)
  Predecessor Horizon Discovery Ltd.
Product Industry drug discovery
Persons Person Pizzie, Terry (Horizon Discovery 201702– before Pacific BiosciencesVP Europe before Genetix + Biacore + ABI)
  Person 2 Vellacott, Richard (Horizon Discovery 201207– CFO before VP Finance at CSR plc before Deloitte)
     
Region Region Waterbeach, Cambridgeshire
  Country United Kingdom (GB)
  City CB25 9TL Cambridge, Cambridgeshire
    Address record changed: 2016-07-24
     
Basic data Employees n. a.
  Currency GBP
  Annual sales 20,156,000 (revenue, consolidated (2015) 2015-12-31)
  Profit -9,883,000 (2015-12-31)
  Cash 25,067,000 (2015-12-31)
     
    * Document for �About Section�: Horizon Discovery Ltd.. (4/30/12). "Press Release: Horizon Discovery and H3 Biomedicine Collaborate to Identify and Validate Novel Cancer Targets". Cambridge & Cambridge, MA.
     
   
Record changed: 2018-11-21

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Horizon Discovery (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px




» top